Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
A Comparative Study of Al18F-NOTA-LM3 Versus 68Ga-DOTATATE PET/CT for Tumor Detection in Patients With Pheochromocytoma and Paraganglioma
Peking Union Medical College Hospital
40 participants
Aug 6, 2024
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
Eligibility
Inclusion Criteria2
- Patients aged 18 to 80 years.
- Suspected or confirmed PPGL patients.
Exclusion Criteria4
- Combined with other types of tumors.
- Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR<30ml/min).
- Pregnant or breast-feeding women.
- Inability to perform PET/CT scans.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive a single intravenous injection of Al18F-NOTA-LM3. Subsequently, a PET/CT scan will be performed within 60 to 120 minutes post-injection.
Patients will receive a single intravenous injection of 68Ga-DOTATATE. Subsequently, a PET/CT scan will be performed within 40 to 60 minutes post-injection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07288931